The Atopic Dermatitis Drugs market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The atopic dermatitis drugs market is likely to expand substantially in the years to come owing to progress made in various drug classes. Atopic dermatitis (AD) is a chronic or chronically relapsing hypersensitive manifestation of the skin with itching as a predominant feature. Growth of the market is ascribed to the awareness about available treatment options amongst the people. Primarily, the growth of the regional market is due to early adoption of new medications, increased collaboration between pharmaceutical companies, improved healthcare infrastructure, and better reimbursement policies. All such factors combines add to the growth of the Indian atopic dermatitis drugs market during the forecast timeframe.
The Indian atopic dermatitis drugs market is expected to be primarily driven by the rising occurrences of atopic dermatitis drugs, continued investment into the national healthcare system and services, growing prevalence of food allergies exacerbating atopic dermatitis, growing focus on systematic therapies, increasing use of pharmacological products in India, substantial atopic dermatitis patient population that is anticipated to grow over the coming decade. Poor patient adherence due to inadequate information on drug usage is the major factor hindering the atopic dermatitis drugs market. In addition, replacement of second-line and primary therapies along with premium-priced drugs is likely to offer ample scope of growth of the market.